Assessment Activity 2026 - 2027

Beyond Ozempic: Building a Responsible Global Strategy for the Weight-Loss Medicine Revolution

GLP-1 medicines may transform the treatment of obesity and related chronic diseases. Yet rapid demand, social-media influence, unequal access, high costs, medical uncertainty, and commercial pressure create a difficult global challenge. How should governments, healthcare providers, pharmaceutical companies, insurers, and communities build a system that makes these treatments safe, equitable, financially sustainable, and socially responsible?

The Weight-Loss Revolution: Designing Responsible Access to GLP-1 Medicines

Obesity is increasingly treated as a chronic and complex health condition rather than simply an individual failure of discipline. In December 2025, the World Health Organization issued its first global guidance supporting the conditional use of GLP-1 therapies as part of comprehensive, long-term obesity care for adults. The WHO also emphasized that medication alone cannot solve obesity and raised concerns about cost, supply, healthcare capacity, and unequal access.

At the same time, the social narrative surrounding these medicines is moving faster than medical systems. Celebrity culture, before-and-after content, influencers, telehealth advertising, body-image expectations, and online misinformation can shape demand. Regulators have also warned about misleading promotion, fraudulent products, unapproved compounded versions, and dosing errors.

The result is an excellent strategic tension:

Are GLP-1 medicines a historic public-health breakthrough, an expensive pharmaceutical dependency, a consumer lifestyle product—or all three at once?

Central decision challenge

A government, health ministry, insurer, or international healthcare coalition must design a five-year strategy for the responsible use of GLP-1 medicines.

The organization must decide:

• Who should qualify for treatment;
• Whether public healthcare systems should pay;
• How medicines should be prescribed and monitored;
• How shortages and inappropriate use should be managed;
• How misinformation and social pressure should be addressed;
• How prevention, nutrition, exercise, mental well-being, and medical treatment should work together;
• How access can remain equitable across income groups and countries.

Rather than saying that governments are broadly “encouraging Ozempic,” I would frame it more carefully:

Governments and health systems are evaluating whether and how GLP-1 medicines should be incorporated into publicly funded obesity care.

Policies differ substantially according to clinical eligibility, cost, national healthcare budgets, supply, and regulatory approval.

The economic dimension

Students could examine whether governments save money by paying for expensive long-term treatment now in order to reduce future costs associated with diabetes, cardiovascular disease, kidney disease, disability, and lost productivity.

Obesity already creates a significant economic burden. OECD analysis estimates that conditions associated with high body mass place major pressure on healthcare spending and economic productivity. Across OECD countries with comparable data, average reported obesity prevalence increased from approximately 13% in 2003 to 19% in 2023.

Economic questions could include:

• Should medication be publicly reimbursed?
• Should eligibility depend on health risk rather than weight alone?
• Can healthcare systems afford long-term treatment for millions of people?
• Could negotiated pricing or generic competition improve access?
• Would widespread treatment reduce future healthcare expenses?
• What happens when patients stop treatment?
• How should limited supplies be allocated between diabetes and obesity care?
• Will private access deepen inequality between richer and poorer populations?

The social and ethical dimension

The issue is not merely medical. It affects how society understands bodies, responsibility, health, attractiveness, and personal success.

Students could examine:

• Whether the medicines reduce stigma by recognizing obesity as a chronic condition;
• Whether they reinforce pressure to become thinner;
• How social media turns medical treatment into a beauty trend;
• Whether people feel compelled to disclose that they use medication;
• Whether users are judged as “taking the easy way out”;
• How access differs by income, geography, gender, culture, and healthcare coverage;
• Whether workplace or insurance discrimination could emerge;
• How public campaigns can promote health without shaming people’s bodies.

The case should avoid asking students whether individuals “deserve” treatment. A stronger ethical question is:

How can society support informed medical choice without creating new forms of stigma, coercion, or body dissatisfaction?

The creative and marketing dimension

The creative challenge could be to develop a global awareness campaign that is medically responsible but still compelling.

Students could design:

• A public-information campaign;
• A social-media misinformation strategy;
• A physician–patient decision tool;
• A digital treatment-support platform;
• A responsible advertising code;
• A campaign distinguishing medical treatment from cosmetic trends;
• A packaging or pharmacy information system;
• A public dashboard explaining benefits, limitations, eligibility, and access;
• A storytelling campaign using patient, physician, and public-health perspectives.

The challenge is especially interesting because traditional weight-loss advertising frequently relies on aspiration and appearance, whereas responsible healthcare communication must emphasize evidence, informed consent, realistic expectations, and medical supervision.

A possible creative brief would be:

Create a global communication strategy that increases informed awareness of GLP-1 medicines without promoting self-diagnosis, unrealistic body expectations, or inappropriate demand.

The political and regulatory dimension

Governments must balance several competing responsibilities:

Students could compare different policy models:

Universal clinical access

Eligible patients receive publicly funded treatment based on medical criteria.

Benefit: Broad and equitable access.
Risk: High costs and pressure on healthcare capacity.

High-risk priority model

Public coverage is limited to people with obesity and serious related health risks.

Benefit: Directs resources toward those most likely to benefit.
Risk: Excludes people who may benefit from earlier intervention.

Private-market model

Patients generally pay privately, with limited public reimbursement.

Benefit: Reduces immediate government expenditure.
Risk: Creates substantial inequality.

Prevention-first model

Governments prioritize food systems, physical activity, education, and community health, while limiting medication use.

Benefit: Addresses broader causes of obesity.
Risk: May underuse an effective medical treatment for people already living with chronic disease.

A realistic strategy could combine these rather than selecting only one.

A strong competition assignment

A national government has asked your team to develop a five-year strategy for the responsible integration of GLP-1 medicines into its healthcare system. Your proposal must balance clinical benefit, affordability, equitable access, medicine supply, prevention, social influence, and public trust.

Students would be asked to create:

1. An access and reimbursement model
   Define who qualifies, who pays, and how treatment should be prioritized.
2. A responsible communication campaign
   Educate the public without encouraging inappropriate use or reinforcing harmful body ideals.
3. A healthcare ecosystem
   Connect physicians, pharmacists, nutrition professionals, mental-health support, digital monitoring, manufacturers, insurers, and patients.
4. An economic model
   Estimate costs, potential health-system savings, pricing options, and long-term sustainability.
5. An ethical and regulatory framework
   Address advertising, social media, privacy, counterfeit products, supply shortages, and equitable access.
6. A measurement dashboard
   Track health outcomes, treatment continuity, adverse events, access disparities, public understanding, and system costs.